Sign Up to our social questions and Answers Engine to ask questions, answer people’s questions, and connect with other people.
Login to our social questions & Answers Engine to ask questions answer people’s questions & connect with other people.
Lost your password? Please enter your email address. You will receive a link and will create a new password via email.
Please briefly explain why you feel this question should be reported.
Please briefly explain why you feel this answer should be reported.
Please briefly explain why you feel this user should be reported.
Comprehensive review of monoclonal gammopathies of undetermined significance. Risk stratification tools continue to improve. – https://www.ssrd.ch/ordentliche-mitglieder-patienten.html , Promising early-phase trial results for a new disease-modifying therapy in ALS. Hope is tempered by the need for larger confirmatory studies. .
